Abstract
The French contribution to the development of 5-fluorouracil (5-FU) infusion in advanced colorectal cancer includes five randomized trials and specific researches on the 48-hour bimonthly regimen, chronotherapy, and individual dose adaptation. The bimonthly 48-hour LV5-FU bolus and infusion is the standard treatment outside the research protocols and the control arm of the ongoing trials.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Review
MeSH terms
-
Antidotes / therapeutic use
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Chronotherapy
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use*
-
France
-
Humans
-
Infusions, Intravenous
-
Injections, Intravenous
-
Leucovorin / therapeutic use
Substances
-
Antidotes
-
Antimetabolites, Antineoplastic
-
Leucovorin
-
Fluorouracil